[A18-16] Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2018
Commission awarded on 28.02.2018 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Adults with type 2 diabetes mellitus when metformin combined with another oral glucose-lowering medicinal product or with basal insulin does not provide adequate glycaemic control
Depending on therapeutic indication and treatment goal: hint of lesser benefit than under the comparator therapy or added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-38||Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V||Commission completed|